Evidence map›Paper›PMID 30327119›Full record

ArticleEpilepsy research2018

Iron supplements in nursing home patients associated with reduced carbamazepine absorption.

Jae Eun Ahn, Sai Praneeth R Bathena, Richard C Brundage, Jeannine M Conway, Ilo E Leppik, Angela K Birnbaum

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jae Eun AhnDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States; Current affiliation: Pharmacometrics, Pfizer, Inc, Cambridge, Massachusetts, United States.
Sai Praneeth R BathenaDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States.
Richard C BrundageDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States.
Jeannine M ConwayDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States.
Ilo E LeppikDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States; Department of Neurology, University of Minnesota, Minneapolis, Minnesota, United States.
Angela K BirnbaumDepartment of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States. Electronic address: birnb002@umn.edu.
University of Minnesota · USPfizer (United States) · US

Funding

TREATMENT OF PATIENTS WITH PSEUDO-SEIZURESP50NS016308 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BIRNBAUM, ANGELA K · 1985 to 2006
$8.5M
NINDS NIH HHS P50 NS016308
6 · The paper itself

Abstract

Persons in nursing homes receive a number of medications that may interfere with the pharmacokinetics of carbamazepine (CBZ). The aim of our study was to determine factors that may affect the pharmacokinetics of CBZ in elderly nursing home patients.

methodsCBZ concentration data collected from 60 nursing homes across the US were evaluated. Inclusion criteria included residency in a nursing home for at least 2 months, age 65 years or older, a stable dosing regimen of CBZ for at least 4 weeks (considered steady state), available CBZ concentration, and complete information regarding all co-medications. Using a nonlinear mixed-effects model, the data were adequately described by a one-compartment model with first-order absorption and elimination. Goodness-of-fit plots, plausibility of parameter estimates, visual predictive check and nonparametric bootstrap were used to evaluate the models. MAIN

findingsThe final data set consisted of 345 CBZ concentrations from 99 subjects (38 males, 61 females). The population estimate of apparent clearance (CL/F) for a 70-kg person was 3.69 L/hr (RSE 6.9%). Residents were receiving either immediate (93.9%) or extended release (6.1%) formulation of CBZ and the K

conclusionsResults from this pharmacokinetic study indicate that use of iron supplementation is associated with a reduction in absorption of CBZ and may need to be considered when dosing CBZ in patients taking iron supplementation.

Indexed as

AnticonvulsantsCarbamazepineNursing HomesAgedAged, 80 and overDietary SupplementsDrug MonitoringEpilepsyFemaleHealth Services for the AgedHumansIndependent LivingIronMaleStatistics, NonparametricUnited StatesAnticonvulsantsCarbamazepineIronCarbamazepineIron supplementsNursing home elderlyPharmacokinetics

Identifiers

PMID30327119
PMCPMC11006430
OpenAlexW2897748667

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.